Tags : Terminates

AbbVie Terminates Tau and ASN Agreement with Voyager Signed in

Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized […]Read More

Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines

Shots: Synlogic regains all rights to develop Synthetic Biotic medicines for all effectors targeting IBD. The termination allows Synlogic to deploy its expertise in strain engineering, quantitative biology, regulatory, and manufacturing of living medicines for expanding its wholly GI-based program portfolio to include IBD Regaining WW rights to develop treatments for IBD allows Synlogic to […]Read More

RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106

Shots: RedHill regains exclusive WW rights for RHB-106 signed in 2014, encapsulated formulation for bowel preparation In 2014, RedHill signed a license agreement with Salix to commercialize RHB-106 in specific territories. RedHill received $7M up front and up to $5M in milestones, plus royalties RHB-106 is a flavorless, odorless, solid oral encapsulated formulation P-IIa candidate […]Read More

Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx

Shots: Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option In 2017, Novartis signed an option agreement with Akcea for two antisense therapies AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular disease. In Feb 2019 Novartis exercised its option for AKCEA-APO(a)-LRx due to strategic portfolio reason , further decided not […]Read More

Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics

Shots: Pear Therapeutics will solely be responsible for commercialization of its prescription digital therapeutics (PDTs), reSET and reSET-O, therapies to treat substance use disorder (SUD) and opioid use disorder (OUD) respectively In Apr’2018, the companies collaborated to develop and commercialize PDTs. The termination of prescription app deal is a part of Sandoz transformation and subsequent […]Read More

Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista

Shots: Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista for T1D & T2D and coordinate with Sanofi in the transition of ongoing clinical studies and other activities In Jul’2019, Sanofi has terminated its 4yrs. […]Read More

Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program

Shots: The three P-III studies (SOTA-MET, SOTA-CKD3, SOTA-CKD4) involves assessing of Zynquista vs PBO in patients with T2D. The first two studies resulted in meeting its 1EPs i.e, @26wks. reduction in HbA1c while SOTA-CKD4 did not demonstrate a reduction in HbA1c Additionally, Sanofi to terminates its development and commercialization agreement with Lexicon for Zynquista in […]Read More